CannaPharmaRX, Inc.
CPMD
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 110.31% | -- | 1,199.61% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.31% | -- | 1,199.61% | -- | -- |
| Cost of Revenue | 64.09% | 397.55% | 12.88% | 3,245.73% | -- |
| Gross Profit | -23.53% | -262.43% | 29.85% | -2,510.67% | -- |
| SG&A Expenses | 210.14% | -41.81% | -49.92% | 79.83% | -72.96% |
| Depreciation & Amortization | -- | -- | -- | 9.16% | -- |
| Other Operating Expenses | -- | -- | -- | -49.00% | -- |
| Total Operating Expenses | 92.28% | 96.41% | -8.41% | 383.80% | 24.06% |
| Operating Income | -81.32% | -51.68% | 37.56% | -315.46% | 22.70% |
| Income Before Tax | -884.39% | -126.36% | 94.11% | -149.58% | 133.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -884.39% | -126.36% | 94.11% | -149.58% | 133.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -884.39% | -126.36% | 94.11% | -149.58% | 133.38% |
| EBIT | -81.32% | -51.68% | 37.56% | -315.46% | 22.70% |
| EBITDA | -- | -73.15% | 36.18% | -275.09% | -13.28% |
| EPS Basic | -833.33% | -125.93% | 97.01% | -126.54% | 115.79% |
| Normalized Basic EPS | -800.00% | -120.31% | 96.83% | -975.00% | 116.67% |
| EPS Diluted | -833.33% | -125.93% | 97.01% | -126.54% | 115.79% |
| Normalized Diluted EPS | -800.00% | -120.31% | 96.83% | -975.00% | 116.67% |
| Average Basic Shares Outstanding | 0.00% | 0.69% | 89.01% | 85.27% | 124.50% |
| Average Diluted Shares Outstanding | 0.00% | 0.69% | 89.01% | 85.27% | 124.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |